A recent study showed that a soluble form of TREM2 (sTREM2) with skipping of the fourth exon (i.e., protein lacking the transmembrane domain) has increased expression in AD patients and could be used as a biomarker for AD [26]. The gene discussed is TREM2; the disease is Alzheimer disease.